Frontiers in Psychiatry
2023
Deborah Rudin, Alexander Areesanan, Matthias E. Liechti et al.
9 citations
Classic psychedelics have been shown to exert therapeutic potential for the treatment of various psychiatric disorders, neuropsychiatric diseases, and neuronal damage. Besides their psychopharmacological activity, psychedelics have been reported to modulate immune functions. There has thus far been a sparse exploration of the direct immune-modulating effect of psychedelics on human immune cells...
International medical case reports journal
2023
Daniel A Kinderlehrer
7 citations
Lyme disease can result in severe neuropsychiatric symptoms that may be resistant to treatment. The pathogenesis of neuropsychiatric Lyme disease is associated with autoimmune induced neuroinflammation. This case report describes an immunocompetent male with serologically positive neuropsychiatric Lyme disease who did not tolerate antimicrobial or psychotropic medications and whose symptoms...
Neuroscience of Consciousness
2023
Sidath Rankaduwa, Adrian M. Owen
21 citations
Given their recent success in counseling and psychiatry, the dialogue around psychedelics has mainly focused on their applications for mental health. Insights from psychedelic research, however, are not limited to treating mental health, but also have much to offer our current understanding of consciousness. The investigation of psychedelic states has offered new perspectives on how different...
Frontiers in Pharmacology
2023
Nataliya S. Vorobyeva, Alena A. Kozlova
1 citation
correction
• please read through all the templates before choosing • pick the most relevant text template(s) from the following page and delete all others. • edit the text as necessary, ensuring that the original incorrect text is included for the record, please see the below. • please do not use any extra formatting when editing the templates, and only modify the red text unless absolutely necessary •...
Journal of Psychoactive Drugs
2023
Daniel J. Kruger, Oskar Enghoff, Moss Herberholz et al.
24 citations
There is a surge of interest in psychedelics, including new stakeholders and greater media attention. There is a need to examine the information-seeking behavior of people using psychedelics naturalistically, given the importance of preparation and harm-reduction. We examined sources of information for people using psychedelics naturalistically, and the degree to which they are trusted in a...
Therapeutic Advances in Psychopharmacology
2023
Ricarda Evens, Tomislav Majić, Timo Torsten Schmidt et al.
49 citations
Background: Classic serotonergic psychedelics have anecdotally been reported to show a characteristic pattern of subacute effects that persist after the acute effects of the substance have subsided. These transient effects, sometimes labeled as the ‘psychedelic afterglow’, have been suggested to be associated with enhanced effectiveness of psychotherapeutic interventions in the subacute period....
Current geriatrics reports
2023
Emily Whinkin, Moira Opalka, Conor Watters et al.
26 citations
This review article summarizes clinically and socially relevant developments over the past five years in the therapeutic use of the classical tryptamine psychedelic substance psilocybin, with respect to the common challenges faced by palliative care patients and their care teams. Psilocybin is available in whole fungal and isolated forms but is not yet approved for therapeutic use in the United...
Progress in Brain Research
2023
Vasileia Kotoula, Jennifer W. Evans, Claire Punturieri et al.
17 citations
Imaging studies of treatment-resistant depression (TRD) have examined brain activity, structure, and metabolite concentrations to identify critical areas of investigation in TRD as well as potential targets for treatment interventions. This chapter provides an overview of the main findings of studies using three imaging modalities: structural magnetic resonance imaging (MRI), functional MRI...
Progress in Brain Research
2023
Mu-Hong Chen, Pei-Chi Tu, Tung-Ping Su
3 citations
Evidence has suggested that the modulation of N-methyl-d-aspartate receptors (NMDARs) and 5-hydroxytryptamine receptors (5-HTRs) via the psychedelic drugs, such as ketamine and psilocybin, rapidly alters the state of consciousness and the neuroplasticity. The United State Food and Drug Administration approved the indications of esketamine for treatment-resistant depression (TRD) in 2019 and...
Frontiers in Psychiatry
2023
Angela N Phan, Garth E Terry
6 citations
Cannabis use disorder (CUD) is prevalent in ~2-5% of adults in the United States and is anticipated to increase as restrictions to cannabis decrease and tetrahydrocannabinol (THC) content in cannabis products increase. No FDA-approved medications for CUD are currently available, despite trials of dozens of re-purposed and novel drugs. Psychedelics have garnered interest as a therapeutic class...
Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion
2023
María T Rivera-García, Silvia L. Cruz
8 citations
Since the dawn of civilization, ancient cultures have utilized hallucinogens from plants and fungi in the context of religious and healing practices. Recently, their use has expanded to other cultures. Hallucinogens are natural or synthetic substances that alter the perception of reality at nontoxic doses, producing intense psychological and physiological effects. The initial research on...
Frontiers in Psychology
2023
Otto Simonsson, Cecilia U.D. Stenfors, Simon B. Goldberg et al.
4 citations
Previous research suggests that mindfulness meditation and psychedelic substances show promise as mental health interventions, but relatively little remains known about their potential impact on leadership outcomes. This study aimed to investigate if and how mindfulness meditation and psychedelic use may impact leadership among respondents with a management position as their primary role at...
Neurotrauma reports
2023
Stephanie Karzon Abrams, Brenden Samuel Rabinovitch, Rayyan Zafar et al.
5 citations
Psychedelic-assisted therapy (PAT) may treat various mental health conditions. Despite its promising therapeutic signal across mental health outcomes, less attention is paid on its potential to provide therapeutic benefits across complex medical situations within rehabilitation medicine. Persons with spinal cord injury (SCI) have a high prevalence of treatment-resistant mental health...
Expert Review of Neurotherapeutics
2023
Emmanuelle A. D. Schindler, Peter S. Hendricks
5 citations
While the majority of current research and development surrounds depression, demoralization, and substance use disorders, there are numerous reports of psychedelics having beneficial effects in other branches of medicine, including for headache disorders and chronic pain. This perspective reviews conventional forms of treatment for headache and other chronic pain disorders and describes...
Neuropsychiatric Disease and Treatment
2023
Kwonmok Ko, Ben Carter, Anthony J. Cleare et al.
26 citations
In psychedelic therapy, mystical as well as challenging experience may influence therapeutic outcome. However, predictors of such experience have not been sufficiently established. Determining predictors of their intensity is, therefore, potentially beneficial in targeting psilocybin therapy for depression. In a post hoc data analysis of a Phase 1, randomised, double-blind, placebo-controlled,...